EMA to consider expanding use of Merck/Pfizer’s Bavencio
The regulator will assess its safety and efficacy as a treatment for bladder cancer
Read Moreby Selina McKee | Jun 22, 2020 | News | 0
The regulator will assess its safety and efficacy as a treatment for bladder cancer
Read Moreby Anna Smith | Jan 7, 2020 | News | 0
Last year the drug disappointed in the Phase III JAVELIN Gastric 100 study, but has pulled itself back with new urothelial carcinoma data.
Read Moreby Selina McKee | Mar 20, 2019 | News | 0
Merck and Pfizer are pulling the plug on a late-stage trial assessing the potential of their PD-L1 antibody avelumab in the front-line maintenance setting for ovarian cancer.
Read Moreby Anna Smith | Mar 8, 2019 | News | 0
European regulators have validated Merck’s application Bavencio for review in kidney cancer.
Read Moreby Anna Smith | Jan 3, 2019 | News | 0
Pfizer and Merck KGaA have announced that they will be terminating the Phase III JAVELIN Ovarian 100 study of Bavencio, as the data did not support the study’s initial hypothesis.
Read Moreby Selina McKee | Nov 6, 2017 | News | 0
Merck and Pfizer have launched in the UK of Bavencio, the first medicine to be licensed for the treatment of the rare, aggressive skin cancer of metastatic Merkel Cell Carcinoma (mMCC).
Read Moreby Selina McKee | Jul 8, 2016 | News | 0
Pfizer and Germany’s Merck have kicked off a large-scale, late-stage study assessing their immunotherapy avelumab in ovarian cancer.
Read More





PharmaTimes Media Ltd.
44 Maiden Lane
Covent Garden
London
WC2E 7LN
E: editorial@pharmatimes.com
E: subscriptions@pharmatimes.com
T: +44 (0)20 7240 6999
